[Federal Register Volume 59, Number 25 (Monday, February 7, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-2652]
[[Page Unknown]]
[Federal Register: February 7, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Consensus Development Conference on Effects of Corticosteroids
for Fetal Maturation on Perinatal Outcomes
Notice is hereby given of the NIH Consensus Development Conference
on ``Effects of Corticosteroids for Fetal Maturation on Perinatal
Outcomes,'' which will be held February 28-March 2, 1994, in the Masur
Auditorium of the National Institutes of Health, 9000 Rockville Pike,
Bethesda, Maryland 20892. This conference is sponsored by the National
Institute of Child Health and Human Development and the NIH Office of
Medical Applications of Research. The conference is cosponsored by the
National Heart, Lung, and Blood Institute and the National Institute of
Nursing Research. The conference begins at 8:30 a.m. on February 28, 8
a.m. on March 1, and 9 a.m. on March 2. The meeting is open to the
public at no charge.
One of a series of NIH Consensus Development Conferences, this
conference will evaluate the data available related to antenatal
corticosteroid treatment of pregnant women delivering prematurely. The
conditions and purposes of this treatment will be reviewed, as well as
its short-term and long-term benefits and adverse effects. In addition,
the economic consequences of this treatment will be considered.
After 1\1/2\ days of presentations and discussion by the audience,
an independent non-Federal consensus panel will weigh the scientific
evidence and write a draft consensus statement in response to the
following key questions:
For what conditions and purposes are antenatal
corticosteroids used, and what is the scientific basis for that use?
What are the short-term and long-term benefits of
antenatal corticosteroid treatment?
What are the short-term and long-term adverse effects for
the infant and mother?
What are the economic consequences of this treatment?
What is the influence of type of corticosteroid, dosage,
timing and circumstances of administration, and associated therapy on
treatment outcome?
What are the recommendations for use of antenatal
corticosteroids?
What research is needed to guide clinical care?
On the final day of the meeting, the consensus panel chairman will
read the draft statement to the conference audience and invite comments
and questions.
Advance information on the conference program and conference
registration materials may be obtained from: Debra Steward, Technical
Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland
20852, phone (301) 770-3153.
A draft report will be prepared before the conference by the
consensus panel, providing preliminary information on the issues
described above. Advance copies of this report will be available to the
public by January 15, 1994. Interested persons or organizations may
obtain a copy of this draft report from: Debra Steward, Technical
Resources, Inc., 3202 Tower Oaks Blvd., suite 200, Rockville, Maryland
20852, phone (301) 770-3153.
Those individuals wishing to make comments on the draft report may
submit their comments in writing by February 14, 1994, to Mr. Jerry
Elliott, Office of Medical Applications of Research, National
Institutes of Health, Federal Building, Room 618, Bethesda, Maryland
20892. Individuals may also present their comments during discussion
periods at the conference. Written comments and discussion at the
conference will be used to prepare the final panel report, which will
be available approximately October 1, 1994. Statements received after
the meeting cannot be considered by the panel in preparing their final
report.
On the second day of the conference, time has been allocated for 5-
10 minute formal oral presentations by concerned individuals or
organizations. Those individuals or groups wishing to send a
representative to contribute during this session must contact Mr. Jerry
Elliott by 5 p.m. EST, February 14, 1994, at: Office of Medical
Applications of Research, National Institutes of Health, Federal
Building, room 618, Bethesda, Maryland 20892, phone (301) 496-1144.
The final consensus statement, a document separate from the panel
report, will be submitted for publication in professional journals and
other publications. The final consensus statement will be available
approximately April 1, 1994. Requests for the final consensus statement
should be addressed to the NIH Consensus Program Information Service,
P.O. Box 2577, Kensington, Maryland 20891, phone 1-800-NIH-OMAR (1-800-
644-6627).
Dated: January 28, 1994.
Harold Varmus,
Director, NIH.
[FR Doc. 94-2652 Filed 2-4-94; 8:45 am]
BILLING CODE 4140-01-M
